Three young men detained in Moscow for throwing flares at US ambassador’s residenceWorld October 25, 22:02
Kremlin gives no comment on alleged US carte blanche to Russia for Aleppo operationRussian Politics & Diplomacy October 25, 21:44
German ARD TV channel to go any length to win case against Russian athlete — lawyerSport October 25, 21:24
Russian, German top diplomats discuss humanitarian situation in Aleppo — ministryRussian Politics & Diplomacy October 25, 20:09
Russia moves up to 40th place in Doing Business-2017 rating — World BankBusiness & Economy October 25, 20:04
Russia hopes to receive roadmap from IPC on Paralympic membership soonSport October 25, 20:03
Lukoil warns about fake "namesake" company in UKBusiness & Economy October 25, 19:39
Russia keeps urging West to set up wide coalition against terrorismRussian Politics & Diplomacy October 25, 19:37
The farthest shore: peaceful images of Russia's Primorsky KraiSociety & Culture October 25, 19:17
MOSCOW, April 14 (Itar-Tass) —— The Russian Skolkovo innovation centre’s resident company is developing innovative medicines against AIDS.
“These medicines use an absolutely new mechanism of action. Molecules affect structural protein that is critical for the HIV virus,” Quantum Pharmaceuticals Deputy Director Maxim Kholin said in an exclusive interview with Itar-Tass.
“The mechanism of action has its peculiarities and they allow us to expect our medicines to be less toxic for the human organism than many others now available. This is very important because the development of medicines against HIV is facing two problems: the virus is highly variable and medicines are toxic,” Kholin noted.
“We are continuing research and getting good results,” he added.
“Skolkovo has supported our project and helped us move forward considerably. It’s important to say that the substances have been developed using our own molecular modelling technology, one of the leading technologies in the world. We also actively use this technological platform for developing other antiviral medicines, new cancer medications and antibiotics. We work both on our own and in partnership with leading international research centres,” Kholin said.